FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1747584008> ?p ?o ?g. }

• W1747584008 endingPage "1835" @default.
• W1747584008 startingPage "1829" @default.
• W1747584008 abstract "// Franco Venanzi 1,* , Victor Shifrin 2,* , Michael Y. Sherman 3 , Vladimir Gabai 2 , Oleg Kiselev 4 , Andrey Komissarov 4 , Mikhail Grudinin 4 , Maria Shartukova 4 , Ekaterina A. Romanovskaya-Romanko 4 , Yuri Kudryavets 5 , Natalya Bezdenezhnykh 5 , Oleksandra Lykhova 5 , Nadiia Semesyuk 5 , Antonio Concetti 1 , Anatoly Tsyb 6 , Marina Filimonova 6 , Victoria Makarchuk 6 , Raisa Yakubovsky 7 , Andrey Chursov 2 , Vita Shcherbinina 2 and Alexander Shneider 2 1. Laboratory of Translational Biology, Department of Biology MCA, University of Camerino, 62032, Italy 2. CureLab Oncology, Inc, Needham, MA, 02492, USA 3. Dept Biochem, Boston University School of Medicine, Boston MA, 02118, USA 4. Research Institute of Influenza, St-Petersburg, 197376, Russia 5. R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NAS of Ukraine, Kiev, 03022, Ukraine 6. Medical Radiology Reseach Center, Obninsk, 249036, Russia 7. Gertzen Research Oncology Institute, Moscow, 125284, Russia * These authors contributed equally Correspondence: Alexander Shneider, email: // Keywords : cancer immunotherapy, DNA vaccine, autophagy, metastases Received : September 10, 2013 Accepted : September 30, 2013 Published : October 2, 2013 Abstract Autophagy plays an important role in neoplastic transformation of cells and in resistance of cancer cells to radio- and chemotherapy. p62 (SQSTM1) is a key component of autophagic machinery which is also involved in signal transduction. Although recent empirical observations demonstrated that p62 is overexpressed in variety of human tumors, a mechanism of p62 overexpression is not known. Here we report that the transformation of normal human mammary epithelial cells with diverse oncogenes (RAS, PIK3CA and Her2) causes marked accumulation of p62. Based on this result, we hypothesized that p62 may be a feasible candidate to be an anti-cancer DNA vaccine. Here we performed a preclinical study of a novel DNA vaccine encoding p62. Intramuscularly administered p62-encoding plasmid induced anti-p62 antibodies and exhibited strong antitumor activity in four models of allogeneic mouse tumors – B16 melanoma, Lewis lung carcinoma (LLC), S37 sarcoma, and Ca755 breast carcinoma. In mice challenged with Ca755 cells, p62 treatment had dual effect: inhibited tumor growth in some mice and prolonged life in those mice which developed tumor size similar to control. P62-encoding plasmid has demonstrated its potency both as a preventive and therapeutic vaccine. Importantly, p62 vaccination drastically suppressed metastasis formation: in B16 melanoma where tumor cells where injected intravenously, and in LLC and S37 sarcoma with spontaneous metastasis. Overall, we conclude that a p62-encoding vector(s) constitute(s) a novel, effective broad-spectrum antitumor and anti-metastatic vaccine feasible for further development and clinical trials." @default.
• W1747584008 created "2016-06-24" @default.
• W1747584008 creator A5000849551 @default.
• W1747584008 creator A5002957617 @default.
• W1747584008 creator A5004182750 @default.
• W1747584008 creator A5007966750 @default.
• W1747584008 creator A5018060071 @default.
• W1747584008 creator A5019032161 @default.
• W1747584008 creator A5029570465 @default.
• W1747584008 creator A5033237393 @default.
• W1747584008 creator A5039346624 @default.
• W1747584008 creator A5040873668 @default.
• W1747584008 creator A5042457211 @default.
• W1747584008 creator A5048159214 @default.
• W1747584008 creator A5049555547 @default.
• W1747584008 creator A5052863148 @default.
• W1747584008 creator A5054506010 @default.
• W1747584008 creator A5060673809 @default.
• W1747584008 creator A5067359095 @default.
• W1747584008 creator A5071114781 @default.
• W1747584008 creator A5077137659 @default.
• W1747584008 creator A5078601281 @default.
• W1747584008 creator A5090520853 @default.
• W1747584008 date "2013-10-02" @default.
• W1747584008 modified "2023-10-16" @default.
• W1747584008 title "Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector" @default.
• W1747584008 cites W1594950156 @default.
• W1747584008 cites W1964266353 @default.
• W1747584008 cites W1967035538 @default.
• W1747584008 cites W1981912182 @default.
• W1747584008 cites W1995771017 @default.
• W1747584008 cites W1997112179 @default.
• W1747584008 cites W2017076137 @default.
• W1747584008 cites W2026938943 @default.
• W1747584008 cites W2035239007 @default.
• W1747584008 cites W2046972425 @default.
• W1747584008 cites W2067118877 @default.
• W1747584008 cites W2068302554 @default.
• W1747584008 cites W2074919423 @default.
• W1747584008 cites W2077703512 @default.
• W1747584008 cites W2101871553 @default.
• W1747584008 cites W2103033117 @default.
• W1747584008 cites W2104704977 @default.
• W1747584008 cites W2132802699 @default.
• W1747584008 cites W2154076937 @default.
• W1747584008 cites W2171952135 @default.
• W1747584008 doi "https://doi.org/10.18632/oncotarget.1397" @default.
• W1747584008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3858567" @default.
• W1747584008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24121124" @default.
• W1747584008 hasPublicationYear "2013" @default.
• W1747584008 type Work @default.
• W1747584008 sameAs 1747584008 @default.
• W1747584008 citedByCount "35" @default.
• W1747584008 countsByYear W17475840082014 @default.
• W1747584008 countsByYear W17475840082015 @default.
• W1747584008 countsByYear W17475840082016 @default.
• W1747584008 countsByYear W17475840082017 @default.
• W1747584008 countsByYear W17475840082018 @default.
• W1747584008 countsByYear W17475840082019 @default.
• W1747584008 countsByYear W17475840082020 @default.
• W1747584008 countsByYear W17475840082021 @default.
• W1747584008 countsByYear W17475840082022 @default.
• W1747584008 countsByYear W17475840082023 @default.
• W1747584008 crossrefType "journal-article" @default.
• W1747584008 hasAuthorship W1747584008A5000849551 @default.
• W1747584008 hasAuthorship W1747584008A5002957617 @default.
• W1747584008 hasAuthorship W1747584008A5004182750 @default.
• W1747584008 hasAuthorship W1747584008A5007966750 @default.
• W1747584008 hasAuthorship W1747584008A5018060071 @default.
• W1747584008 hasAuthorship W1747584008A5019032161 @default.
• W1747584008 hasAuthorship W1747584008A5029570465 @default.
• W1747584008 hasAuthorship W1747584008A5033237393 @default.
• W1747584008 hasAuthorship W1747584008A5039346624 @default.
• W1747584008 hasAuthorship W1747584008A5040873668 @default.
• W1747584008 hasAuthorship W1747584008A5042457211 @default.
• W1747584008 hasAuthorship W1747584008A5048159214 @default.
• W1747584008 hasAuthorship W1747584008A5049555547 @default.
• W1747584008 hasAuthorship W1747584008A5052863148 @default.
• W1747584008 hasAuthorship W1747584008A5054506010 @default.
• W1747584008 hasAuthorship W1747584008A5060673809 @default.
• W1747584008 hasAuthorship W1747584008A5067359095 @default.
• W1747584008 hasAuthorship W1747584008A5071114781 @default.
• W1747584008 hasAuthorship W1747584008A5077137659 @default.
• W1747584008 hasAuthorship W1747584008A5078601281 @default.
• W1747584008 hasAuthorship W1747584008A5090520853 @default.
• W1747584008 hasBestOaLocation W17475840081 @default.
• W1747584008 hasConcept C121608353 @default.
• W1747584008 hasConcept C126322002 @default.
• W1747584008 hasConcept C143998085 @default.
• W1747584008 hasConcept C161191863 @default.
• W1747584008 hasConcept C190283241 @default.
• W1747584008 hasConcept C203522944 @default.
• W1747584008 hasConcept C31033888 @default.
• W1747584008 hasConcept C41008148 @default.
• W1747584008 hasConcept C502942594 @default.
• W1747584008 hasConcept C54355233 @default.
• W1747584008 hasConcept C71924100 @default.
• W1747584008 hasConcept C86803240 @default.

• next